MYOK News and Press, MyoKardia Inc. From 10/05/20

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval ...

MyoKardia ( MYOK +0.9% ) has dosed the first patient in Phase 2 trial of danicamtiv (MYK-491) in people with primary dilated cardiomyopathy (DCM), characterized by weakened and enlarged heart muscle, that results in the heart not being able to pump enough blood. More news on: My...

BRISBANE, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused ...

Arrowhead Pharmaceuticals (NASDAQ: ARWR ) announces positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoiet...

EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet Presentation Expands on Positive Topline Results Showing Early, Sustained Reductions in Biomarkers of Cardiac Wall Stress and Myocardial Injury Mavacamten Demo...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Volatility watch: Options volatility is running very high on Whiting Petroleum (NYSE: WLL ) , Sunesis Pharmaceuticals (NASDAQ: SNSS ) and Lipocine (NASDAQ: LPCN ) heading into next week, while notable short interest jumps have been seen with Macerich (NYSE: MAC ) , Teladoc (NYSE: T...

LianBio Launches to Bring US Assets to China; Announces $719 Million of In-Licensings Perceptive Advisors is launching LianBio to bring US biopharma assets to China. A successful fund operator, Perceptive has made investments in 150 public and 80 private biopharmas and has strong connectio...

MyoKardia (NASDAQ: MYOK )   +1.3%  premarket, has announced a license agreement with LianBio, for the development and commercialization of its lead drug candidate, mavacamten for hypertrophic cardiomyopathy (HCM) in China, other Asian territories. More...

Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation:  MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, ...